ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
As a nurse, you play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get the information and tools you need to help support your patients below.
From clinical trial data to monitoring and management information, it’s all here—so you can continue to help your patients feel comfortable and secure throughout their treatment journey.
RRMM=relapsed/refractory multiple myeloma.
With durable efficacy data and the most real-world experience of any CAR T cell therapy in RRMM, ABECMA may help your patients focus on their freedom after a one-time infusion.
(95% CI, 63.2-80.8)
(95% CI, 44.2-63.8)
(95% CI, 20.1-37.9)
mTTR: 1 month
(range: 0.5-2.9 months)
mDoR†: 11.3 months
(95% CI, 10.3-15.3)
300-460 x 106 CAR-positive T cells (N=100)
The long-term 24-month follow-up analysis was supportive of the median follow-up of 13.2-month (range: 0.2-21.0) data in the USPI (ORR [primary endpoint]: 72%; sCR: 28%; VGPR: 25%; mDoR: 11.0 months).
(95% CI, 6.08-12.22)
(95% CI, 18.96-NE)
OS was a secondary endpoint of KarMMa and was not statistically tested in the setting of a single-arm trial. OS data are not in the USPI and should be interpreted with caution in a single-arm trial. The statistical significance of OS is not known. Median follow-up of 19.9 months (range 0.2-31.5):
KarMMa was an open-label, single-arm, multicenter trial that evaluated the efficacy and safety of ABECMA in adult patients with RRMM who had received at least 3 prior antimyeloma therapies, including an IMiD® agent, a PI, and an anti-CD38 monoclonal antibody. The primary endpoint was ORR (PR or better as assessed by an IRC). Select secondary endpoints included CR, DoR, MRD, OS, PFS, TTR, and safety. Of the 135 patients who underwent leukapheresis, 100 (74%) received ABECMA in the dose range of 300 to 460 x 106 CAR-positive T cells. ABECMA is an autologous product; the manufactured dose for individual patients may vary. The study consisted of pretreatment (leukapheresis and bridging therapy|| [if needed]); treatment (LDC and ABECMA infusion); and post-treatment¶ monitoring. The LDC consisted of cyclophosphamide (300 mg/m2 IV infusion daily for 3 days) and fludarabine (30 mg/m2 IV infusion daily for 3 days) starting 5 days prior to the target infusion date of ABECMA.1,4
While regular check-ins with their healthcare team are still required, the following are NOT required for patients while they are responding to ABECMA1:
Efficacy data based on long-term follow-up analysis (median time from ABECMA infusion to data cutoff 27.3 months [range: 24.1 to 33.1]; N=100). Data were generally consistent with the primary analysis.
Response is defined as achieving ≥PR. Of the 100 patients in the efficacy-evaluable population, 25 (25%) achieved a VGPR (95% CI, 16.5-33.5) and 18 (18%) achieved a PR (95% CI, 10.5-25.5).7
All complete responses were sCRs.
Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.
Bridging therapy with alkylating agents, corticosteroids, immunomodulatory agents, proteasome inhibitors, and/or anti-CD38 monoclonal antibodies to which patients were previously exposed was permitted for disease control between apheresis and until 14 days before the start of lymphodepleting chemotherapy.
Per the study protocol, patients were monitored at the treatment center for 14 days after ABECMA infusion for potential cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, and neurotoxicity.
CAR=chimeric antigen receptor; CR=complete response; DoR=duration of response; IRC=Independent Response committee; IV=intravenous; LDC=lymphodepleting chemotherapy; mDoR=median duration of response; MM=multiple myeloma; mOS=median overall survival; MRD=minimal residual disease; mTTR=median time to response; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; PI=proteasome inhibitor; PR=partial response; TTR=time to response; sCR=stringent complete response; VGPR=very good partial response.